Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab

Kazumoto Iijima(Kobe Children's Hospital), Kandai Nozu(Kobe Children's Hospital), Hidefumi Nakamura(National Center For Child Health and Development), Kenichiro Miura(Japanese Society for Dialysis Therapy), Ryojiro Tanaka(Kobe Children's Hospital), Koichi Nakanishi(University of the Ryukyus), Hiroshi Kaito(Kobe University), Shori Takahashi(Surugadai Nihon University Hospital), Shuichi Ito(Yokohama City University), Kunihiko Aya(Okayama University), Kenji Ishikura(Kitasato University), Koichi Kamei(National Center For Child Health and Development), Tetsuji Morimoto(Tohoku Medical and Pharmaceutical University Hospital), Mayumi Sako(National Center For Child Health and Development), Yoshiyuki Ohtomo(Juntendo University Nerima Hospital), Wataru Kubota(Tokyo Metropolitan Children's Medical Center)
Pediatric Nephrology
June 29, 2017
10.1007/s00467-017-3718-0
Cited by 54

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial
|The Lancet|2014|450
IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome
|Pediatric Nephrology|2022|278
Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease
|Clinical and Experimental Nephrology|2013|267
Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies
|Pediatric Nephrology|2021|149
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment
|Kidney International|2014|135